Equities

Taiko Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4574:TYO

Taiko Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)313.00
  • Today's Change5.00 / 1.62%
  • Shares traded271.10k
  • 1 Year change+5.03%
  • Beta0.9546
Data delayed at least 15 minutes, as of Feb 17 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

TAIKO PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company is engaged in three business segments. The Pharmaceutical Product segment is engaged in the manufacturing, sales and export of gastrointestinal drugs under the name SEIROGAN, SEIROGAN TOI-A (sugar coated tablet) and PISHUT. The Infection Control segment is engaged in the planning, development and sales of infection control products, which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacturing and sales of bath liquid, soap and gardening pyroligneous acid.

  • Revenue in JPY (TTM)6.40bn
  • Net income in JPY923.00m
  • Incorporated1946
  • Employees214.00
  • Location
    Taiko Pharmaceutical Co Ltd16F, ORIX Hommachi Bldg1-4-1, Nishihon-machiNishi-kuOSAKA-SHI 550-0005JapanJPN
  • Phone+81 643911110
  • Fax+81 643911199
  • Websitehttps://www.seirogan.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
COSMO BIO COMPANY, LIMITED10.77bn337.00m7.90bn174.0022.100.791215.780.734259.1459.141,893.021,651.940.8836.533.57--2.744.413.245.2434.3935.523.104.884.46--0.00250.687.265.8828.63-12.9434.028.02
Solasia Pharma KK429.00m-876.00m8.08bn23.00--4.51--18.83-3.79-3.791.816.650.24471.842.13---49.96-64.76-58.36-79.6048.4858.61-204.20-297.255.70-61.500.0514--35.76-1.1354.87------
K Pharma Inc0.00-993.23m8.46bn17.00--6.69-----85.59-85.590.00109.000.000.00-----37.53---38.74----------28.29-1,982.810.5424-------17.34------
Wakamoto Pharmaceutical Co Ltd9.29bn298.60m11.11bn286.0037.080.915715.001.208.608.60267.77348.390.60061.623.0632,493,160.001.93-0.06782.22-0.078147.7048.653.21-0.12462.42--0.0082--0.6595-6.53-40.86--21.87--
Stella Pharma Corp968.76m-279.32m12.66bn43.00--4.70--13.07-8.21-8.2128.4779.220.19660.09442.9122,529,260.00-5.67-16.41-5.96-18.1987.8887.03-28.83-176.1613.81-45.690.226--256.62--81.56---21.34--
CellSeed Inc83.68m-1.10bn13.31bn38.00--10.09--159.04-31.83-31.832.4135.670.04090.65613.81---54.00-46.88-59.08-50.9551.0953.64-1,319.46-593.855.81--0.0949---56.71-15.95-28.41--21.04--
Immuno-Biological Laboratories Co., Ltd.1.03bn363.89m15.14bn58.0041.598.5939.5914.6739.0739.07110.76189.250.54560.86034.8117,786,030.0019.25-4.9622.46-5.7770.3562.7035.27-11.273.962,702.080.0947--18.7110.9533.40------
ReproCell Inc2.52bn-324.61m15.45bn99.00--1.76--6.13-3.42-3.4226.6392.820.23284.155.9225,450,770.00-3.00-4.09-3.63-4.4749.3543.75-12.88-13.664.93--0.00--22.7419.94428.65---6.31--
TAIKO PHARMACEUTICAL CO LTD6.40bn923.00m15.60bn214.0016.761.8213.122.4418.3718.37127.34169.510.50801.772.62--7.34-18.999.32-24.0454.4240.2014.44-46.312.72--0.0874--1.67--2.78------
CanBas Co Ltd (Parent)0.00-1.25bn17.39bn14.00--7.31-----64.11-64.110.00120.620.00----0.00-44.48-57.04-46.19-62.13-------4,587.85---566.180.00------4.27------
StemRIM Inc0.00-1.90bn18.62bn45.00--2.71-----30.56-30.560.00109.730.00----0.00-24.08-12.71-24.55-12.88-------167.3547.00--0.00------4.59---22.11--
Ohki Healthcare Holdings Co Ltd359.41bn2.43bn19.01bn648.007.570.55466.720.0529178.43178.4326,346.692,435.832.269.834.34554,637,400.001.531.776.237.745.315.260.6770.69770.8306--0.268614.174.424.7419.412.2145.686.47
Astena Holdings Co Ltd62.74bn2.19bn19.97bn1.42k8.960.72394.340.318354.2254.221,555.72671.410.89613.622.88--3.110.95876.261.7634.8530.403.471.050.9228--0.4519114.258.19-0.808186.601.9712.612.38
Kubota Pharmaceutical Holdings Co Ltd21.34m-676.25m20.31bn19.00--11.20--952.01-10.91-10.910.334115.720.01213.547.98---38.41-44.81-42.10-49.35-14.68---3,169.69-8,411.5912.49--0.0121---21.53-10.8049.26---4.55--
Fuso Pharmaceutical Industries Ltd62.17bn-4.01bn22.43bn1.34k--0.5846--0.3608-469.00-469.007,280.214,059.080.73073.252.3246,394,780.00-4.710.7682-9.761.2926.3926.94-6.441.050.822869.880.4617106.299.315.25-338.78--4.376.45
Data as of Feb 17 2026. Currency figures normalised to Taiko Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

5.97%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 05 Feb 20261.29m2.54%
Amova Asset Management Co., Ltd.as of 06 Feb 2026604.10k1.19%
Daiwa Asset Management Co. Ltd.as of 30 Jan 2026576.60k1.14%
Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Feb 2026267.50k0.53%
BlackRock Japan Co. Ltd.as of 05 Feb 202689.20k0.18%
Asset Management One Co., Ltd.as of 05 Feb 202668.30k0.14%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 05 Feb 202662.30k0.12%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 05 Feb 202628.80k0.06%
Tokio Marine Asset Management Co., Ltd.as of 20 Jun 202522.60k0.05%
Norinchukin Zenkyoren Asset Management Co., Ltd.as of 05 Feb 202614.30k0.03%
More ▼
Data from 31 Dec 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.